Log in

NYSE:GSKGlaxoSmithKline Price Target & Analyst Ratings

-0.64 (-1.55 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $40.55
50-Day Range
MA: $40.88
52-Week Range
Now: $40.55
Volume3.26 million shs
Average Volume3.96 million shs
Market Capitalization$101.72 billion
P/E Ratio12.03
Dividend Yield4.54%

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for GlaxoSmithKline in the last 12 months. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.182.18
Ratings Breakdown: 2 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$45.00$45.00
Price Target Upside: N/AN/A10.78% upside1.31% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2020UBS GroupReiterated RatingBuyLow
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/30/2020BarclaysReiterated RatingUnderweightLow
2/12/2020Shore CapitalDowngradeHold ➝ SellLow
12/2/2019SVB LeerinkInitiated CoverageOutperformLow
10/16/2019New Street ResearchUpgradeReduce ➝ HoldLow
10/11/2019Cantor FitzgeraldUpgradeHold ➝ BuyMedium
9/3/2019Societe GeneraleUpgradeSell ➝ BuyLow
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
6/17/2019Morgan StanleyReiterated RatingUnderweight ➝ UnderweightLow
6/10/2019CowenReiterated RatingHold$45.00Low
1/14/2019Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
12/13/2018SunTrust BanksInitiated CoverageHold$38.00Low
12/4/2018CfraReiterated RatingHoldMedium
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformMedium
10/10/2018Goldman Sachs GroupReiterated RatingBuyLow
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
8/30/2018Liberum CapitalDowngradeBuy ➝ HoldLow
8/20/2018ArgusBoost Price TargetBuy ➝ Buy$45.00 ➝ $47.00Low
8/1/2018Deutsche BankReiterated RatingNeutralLow
7/25/2018Bank of AmericaSet Price TargetHold$40.00Medium
6/14/2018DZ BankReiterated RatingBuyLow
2/9/2018Kepler Capital MarketsUpgradeReduce ➝ HoldLow
11/6/2017InvestecDowngradeBuy ➝ HoldN/A
(Data available from 8/15/2018 forward)
This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.